Regina Scherliess

Title: Innovations of Regina Scherliess in Vaccine Development

Introduction

Regina Scherliess is a notable inventor based in Kiel, Germany, recognized for her contributions to the field of vaccine development. With a total of two patents to her name, she has made significant strides in creating methods and materials that enhance vaccine stability and efficacy.

Latest Patents

One of her latest patents is titled "Method for the production of stabile vaccines." This invention relates to a method for producing stabilized vaccines, which involves mixing antigens with a solution that includes chitosan, at least three different amino acids and/or at least one dipeptide or tripeptide, and a sugar, followed by drying the mixture. Another significant patent is "Antigen-loaded chitosan nanoparticles for immunotherapy." This invention focuses on nanoparticles that comprise chitosan and an antigen, where the chitosan has a degree of deacetylation of about 90% and a molecular weight ranging from 5 kDa to 80 kDa. These particles are designed for use in vaccination.

Career Highlights

Throughout her career, Regina has worked with prominent companies in the pharmaceutical and biotechnology sectors, including Leukocare AG and Merck Patent GmbH. Her work in these organizations has allowed her to develop innovative solutions that address critical challenges in vaccine production and delivery.

Collaborations

Regina has collaborated with esteemed colleagues such as Hartwig Steckel and Martin Scholz, contributing to the advancement of her research and the successful development of her patented technologies.

Conclusion

Regina Scherliess stands out as an influential inventor in the realm of vaccine technology, with her innovative methods and collaborations paving the way for future advancements in immunotherapy. Her work continues to impact the field positively, enhancing the effectiveness of vaccines worldwide.